Abstract
Background Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.
For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.
Objective To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.
Methods Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2018 and September 30, 2024. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.
Results 1,449,442 patients were prescribed a GLP-1 RA between January 2018 and September 2024, with 6,341,367 total prescriptions during this period. Among first-time prescriptions for which use could be established, ADMs accounted for 80.3% and AOMs accounted for 19.7%. The most common first-time medication was semaglutide (n = 821,890). Among those with available data, 69.5% of first-time ADM prescriptions overall and 70.6% in June 2024 had a fill within 60 days. By comparison, 45.4% of first-time AOM prescriptions overall and 50.1% in June 2024 had a fill within 60 days.
Competing Interest Statement
All authors are employees of Truveta, Inc.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 45 C.F.R. Paragraph 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Denotes co-first author
The data has been updated till September 2024.
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.
